Development of novel gene therapy based on the analysis of anti-apoptotic signals in ovarian cancer
基于卵巢癌抗凋亡信号分析的新型基因疗法的开发
基本信息
- 批准号:11470347
- 负责人:
- 金额:$ 9.47万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (B).
- 财政年份:1999
- 资助国家:日本
- 起止时间:1999 至 2000
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Among the gynecological malignant tumors, ovarian carcinoma is most frequently associated with chemoresistance and poor prognosis of the patients. The effect of chemotherapy with various anti-cancer agents including cisplatin is shown to be mediated by intracellular apoptotic signals. Anti-apoptotic factors, either extrinsic or intrinsic, may influence the chemotherapeutic effect, and may result in the chemoresistance of ovarian cancer cells. Therefore, the objective of our study is to analyze the anti-apoptotic signals in ovarian carcinoma cells, and to develop novel gene therapy targeting these anti-apoptotic signals.Our study demonstrated that an approximately half of ovarian carcinomas expressed LH/hCG receptor at both mRNA and protein levels. In ovarian cancer cell line OVCAR3 expressing LH/hCG receptors, hCG inhibited cisplatin-induced apoptosis via up-regulation of IGF-1. IGF-1 also inhibited cisplatin-induced apoptosis and a neutralizing antibody to IGF-1 receptor restored the … More apoptosis. Wortmannin, an inhibitor of phosphatidyl inositol 3-kinase, blocked the anti-apoptotic effect of IGF-1. Therefore, gonadotropin is an important extrinsic factor of anti-apoptotic signal in ovarian cancer cell. Treatment with recombinant adenovirus expressing anti-sense IGF-1 mRNA was effective for restoring the cisplatin-induced apoptosis.Abnormality of p53 tumor suppressor gene is present in more than half of ovarian carcinomas. Pro-apoptotic bax gene is under the regulation of p53, and p53 abnormality resulted in chemoresistance as an intrinsic anti-apototic factor. In vitro, Bax protein expression was attenuated in cisplatin-resistant cell lines such as A2780/cDDP (p53 mutated) and SKOV3 (p53 deleted), compared with cisplatin-sensitive A2780 (p53 wild type). We developed recombinant adenovirus which highly expresses the Bax protein. The Bax protein was successfully induced by treatment with the Bax/adenovirus transfer, and apoptotic effect was obtained in the cisplatin-resistant ovarian cancer cells. Therefore, adenovirus-mediated introduction of Bax may be a useful gene thrapy in the treatment of chemoresistant ovarian carcinomas. Less
在妇科恶性肿瘤中,卵巢癌是最常见的化疗耐药和预后不良的患者。用包括顺铂在内的各种抗癌剂进行化疗的效果显示出由细胞内凋亡信号介导。外源性或内源性抗凋亡因子可能影响化疗效果,并可能导致卵巢癌细胞的化疗耐药。因此,我们的研究目的是分析卵巢癌细胞中的抗凋亡信号,并开发针对这些抗凋亡信号的新的基因治疗方法。我们的研究表明,大约一半的卵巢癌细胞在mRNA和蛋白水平上都表达LH/hCG受体。在表达LH/hCG受体的卵巢癌细胞系OVCAR 3中,hCG通过上调IGF-1抑制顺铂诱导的凋亡。IGF-1还抑制顺铂诱导的细胞凋亡,IGF-1受体的中和抗体恢复了顺铂诱导的细胞凋亡。 ...更多信息 凋亡磷脂酰肌醇3-激酶抑制剂渥曼青霉素阻断IGF-1的抗凋亡作用。因此,促性腺激素是卵巢癌细胞抗凋亡信号的重要外源性因子。用表达反义IGF-1 mRNA的重组腺病毒治疗可有效地恢复顺铂诱导的细胞凋亡。促凋亡基因bax受p53的调控,p53异常作为一种内在的抗凋亡因子导致化疗耐药。在体外,与顺铂敏感的A2780(p53野生型)相比,Bax蛋白在顺铂耐药细胞系如A2780/cDDP(p53突变型)和SKOV 3(p53缺失型)中的表达减弱。我们研制了高表达Bax蛋白的重组腺病毒。Bax/腺病毒转染成功诱导了Bax蛋白的表达,并在卵巢癌顺铂耐药细胞中获得了凋亡效应。因此,腺病毒介导的Bax基因导入可能是一个有用的基因治疗在化疗耐药的卵巢癌。少
项目成果
期刊论文数量(44)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Horiuchi,A., et al.: "Enhancement of antitumor effect of bleomycin"International Journal of Cancer. 88. 640-644 (2000)
Horiuchi,A., et al.:“博来霉素抗肿瘤作用的增强”国际癌症杂志。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Tsuruta,Y., et al: "Combination effect of pro-apoptotic Bax gene transfer"European Journal of Cancer. (印刷中). (2001)
Tsuruta, Y. 等人:“促凋亡 Bax 基因转移的组合效应”,《欧洲癌症杂志》(出版中)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Shimizu,M., et al: "Immunohistochemical detection of the Wilms'tumor gene"International Journal of Gynecdogical Pathology. 19. 158-163 (2000)
Shimizu,M.,等人:“Wilms肿瘤基因的免疫组织化学检测”国际妇科病理学杂志。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Mandai, M.: "A novel approach to modulate the expression of apoptosis-related genes as a treatment strategy of chemo-resistant ovarian cancer."Acta Obst Gynaec Jpn. 51. 575-585 (1999)
Mandai, M.:“一种调节细胞凋亡相关基因表达的新方法,作为化疗耐药性卵巢癌的治疗策略。”Acta Obst Gynaec Jpn。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Kuroda,H., et al.: "Human ovarian surface epithelial (OSE) cells express"International Journal of Cancer. 92. 309-315 (2001)
Kuroda, H. 等人:“人卵巢表面上皮 (OSE) 细胞表达”国际癌症杂志。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KONISHI Ikuo其他文献
KONISHI Ikuo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KONISHI Ikuo', 18)}}的其他基金
Develop of ovarian cancer stem cell specific immunotherapy based on DNA microarray analysis
基于DNA微阵列分析的卵巢癌干细胞特异性免疫疗法的开发
- 批准号:
23659777 - 财政年份:2011
- 资助金额:
$ 9.47万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Evolution of ovarian carcinoma cells through peritoneal dissemination ; genome-wide analysis and clinical application.
卵巢癌细胞通过腹膜播散的进化;
- 批准号:
21390452 - 财政年份:2009
- 资助金额:
$ 9.47万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Analysis of signaling pathways in peritoneal dissemination of ovarian cancer, which leads to investigation for their suppressor reagents.
分析卵巢癌腹膜传播的信号通路,从而研究其抑制试剂。
- 批准号:
19390426 - 财政年份:2007
- 资助金额:
$ 9.47万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of a new molecular target therapy for ovarian carcinoma based on the analyses of mechanisms for its peritoneal dissemination
基于卵巢癌腹膜播散机制分析开发新型分子靶向治疗
- 批准号:
15390502 - 财政年份:2003
- 资助金额:
$ 9.47万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Molecular mechanisms of peritoneal dissemination of ovarian cancer cell, based on the analysis of its microenvironment
基于微环境分析的卵巢癌细胞腹腔播散的分子机制
- 批准号:
13470349 - 财政年份:2001
- 资助金额:
$ 9.47万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Clinicopathological and Molecular Analyses for Possible Correlation between Infertility Therapy and Development of Ocarian Cancer
不孕症治疗与 Ocarian 癌发展之间可能相关性的临床病理学和分子分析
- 批准号:
09470358 - 财政年份:1997
- 资助金额:
$ 9.47万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Molecular-pathologic and clinicopathologic study on the heterogeneity of early development and progression of ovarian cancer
卵巢癌早期发生发展异质性的分子病理学和临床病理学研究
- 批准号:
07457608 - 财政年份:1995
- 资助金额:
$ 9.47万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Role of Heat Shock Proteins in Physiology and Pathology of the Female Genital Tract
热激蛋白在女性生殖道生理学和病理学中的作用
- 批准号:
05454447 - 财政年份:1993
- 资助金额:
$ 9.47万 - 项目类别:
Grant-in-Aid for General Scientific Research (B)
Study on pathogenesis of endometrial carcinomas based on the analysis of growth and differentiation of endometrial gland
从子宫内膜腺生长分化分析子宫内膜癌发病机制
- 批准号:
03670781 - 财政年份:1991
- 资助金额:
$ 9.47万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
去乙酰化酶SIRT1在前体mRNA可变剪切中的作用及其生理病理效应研究
- 批准号:31970691
- 批准年份:2019
- 资助金额:58.0 万元
- 项目类别:面上项目
TM9SF4调控非小细胞肺癌细胞凋亡机制研究
- 批准号:31900527
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
姜黄素与TRAIL的协同抗肿瘤机制研究
- 批准号:31101223
- 批准年份:2011
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
转凝蛋白通过线粒体凋亡途径致足细胞凋亡的机制研究
- 批准号:81100502
- 批准年份:2011
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
相似海外基金
FANCC mutation correction using homology-independent targeted integration for gene therapy of Fanconi Anemia group C
使用同源无关的靶向整合校正 FANCC 突变,用于范可尼贫血 C 组的基因治疗
- 批准号:
10653342 - 财政年份:2023
- 资助金额:
$ 9.47万 - 项目类别:
Anti-eosinophil Gene Therapy for Eosinophilic Esophagitis
抗嗜酸性粒细胞基因治疗嗜酸性粒细胞性食管炎
- 批准号:
10481279 - 财政年份:2022
- 资助金额:
$ 9.47万 - 项目类别:
Retroviral RLI immunomodulatory gene therapy for glioblastoma
逆转录病毒 RLI 免疫调节基因治疗胶质母细胞瘤
- 批准号:
10522026 - 财政年份:2022
- 资助金额:
$ 9.47万 - 项目类别:
Combine mitochondrial gene therapy and synthetic lethal chemotherapy to treat triple-negative breast cancer
结合线粒体基因疗法和合成致死化疗治疗三阴性乳腺癌
- 批准号:
10642815 - 财政年份:2022
- 资助金额:
$ 9.47万 - 项目类别:
Combine mitochondrial gene therapy and synthetic lethal chemotherapy to treat triple-negative breast cancer
结合线粒体基因疗法和合成致死化疗治疗三阴性乳腺癌
- 批准号:
10435099 - 财政年份:2022
- 资助金额:
$ 9.47万 - 项目类别:
Re-engineered Mitochondrially Targeted p53 Gene Therapy in Liver Cancer
重新设计的线粒体靶向 p53 基因疗法治疗肝癌
- 批准号:
10317129 - 财政年份:2021
- 资助金额:
$ 9.47万 - 项目类别:
Immunosuppressive Gene Therapy for Ocular Graft vs Host Disease
眼移植物抗宿主病的免疫抑制基因治疗
- 批准号:
10326039 - 财政年份:2021
- 资助金额:
$ 9.47万 - 项目类别:
Targeted Exosome-Associated AAV-Mediated Gene Therapy to Eliminate Metastatic Neuroendocrine Cancers
靶向外泌体相关 AAV 介导的基因治疗可消除转移性神经内分泌癌
- 批准号:
9907789 - 财政年份:2020
- 资助金额:
$ 9.47万 - 项目类别:














{{item.name}}会员




